The steady state pharaiacokinetic properties of ciprofloxacin and ofloxacin were compared in cystic fibrosis patients. In a cross-over study eighteen adult patients with chronic Pseudomonas aeruginosa lung infection were given either oral ciprofloxacin 750 mg bid or oral ofloxacin 400 mg bid for two weeks. Three months later the alternative treatment was given. Concentrations were determined by a microbiological assay. Mean serum concentrations of ofloxacin (peak 5-9 mg/1) were higher than for ciprofloxacin (peak 4-0 mg/1). The time to reach maximal concentrations did not differ. The apparent total body clearance was significantly greater for ciprofloxacin, but renal clearances were similar. Relative to ofloxacin ciprofloxacin had a significantly shorter serum elimination half-life (3-4 vs. 6-4 h), showed less penetration into sputum (18% vs. 79%) and a lesser amount was recovered in urine (21 % vs. 71 % up to 12 h after dosing). No correlation was found between any pharmacokinetic parameter and change in pulmonary function.
Introduction
The introduction of the fluoroquinolones with a high in-vitro activity against Pseudomonas aeruginosa (Sato et al., 1982; Wise, Andrews & Edwards, 1983) has made successful oral treatment of P. aeruginosa infections possible. Patients with cystic fibrosis (CF) almost inevitably acquire chronic broncho-pulmonary P. aeruginosa infection, which has a poor prognosis without aggressive antipseudomonal chemotherapy (Szaff, Heiby & Flensborg, 1983) , and until recently, only parenteral treatment was available. Effective treatment of pseudomonal infection in CF by oral administration of ciprofloxacin was a major advance (Scully et al., 1986; Smith, Hodson & Batten, 1986a; Rubio & Shapiro, 1986) . Furthermore, in a controlled clinical trial we found ciprofloxacin and its analogue ofloxacin of similar clinical effectiveness in CF patients (Jensen et al., 1987) . The two compounds are, however, not identical in their performance. Thus ciprofloxacin (mol weight 331 g/mol) exhibits a higher activity in vitro against P. aeruginosa from CF patients (Jensen et al., 1987) while treatment with ofloxacin (mol weight 361 g/mol) leads to higher serum concentrations than are observed with ciprofloxacin (Wise et al., 1986) . Meaningful clinical comparisons of these drugs require a knowledge of their pharmacokinetics in relevant patients. The aim of the present study was to compare the steady state pharmacokinetic properties of these two quinolones in CF patients.
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Patients and methods
Study design and patients
The study was part of a prospective, randomized double blind, placebo combined ('double-dummy') cross-over clinical trial. Eighteen CF-patients (9 males, 9 females, mean age 24 years, range 18-36 years) with chronic broncho-pulmonary P. aeruginosa infection were randomly assigned to receive oral treatment with tablets of either ciprofloxacin 750 mg bid plus ofloxacin placebo tablets bid, or ofloxacin 400 mg bid plus ciprofloxacin placebo tablets bid in the first treatment period. Approximately three months after the first period, the alternative treatment was administered. The duration of treatment was 14 days. In both periods pharmacokinetic studies were performed on all patients, who thus served as their own controls. The study was approved by the regional ethics research committee and all patients gave informed consent to participate in the study before entry.
Collection of samples
Samples were collected under steady state conditions, 72-84 h after the first dose between the sixth and seventh doses. The patients were not fasting. Blood for determination of serum concentrations was drawn by repeated venepunctures at 0, 1, 1-5, 2, 4, 8 and 12 h after the drug administration. Blood was allowed to clot at room temperature for 1 h, and serum was separated by centrifugation and stored at -70°C until analysis. Sputum concentrations were determined in 2 ml sputum samples obtained after deep expectoration 2 h after drug intake. The samples were immediately stored at -70°C before the sol phase was separated by ultracentrifugation at 105,000g for 4 h. The sol phase was stored at -70°C until assay of drug concentration. Urine was collected 0-4, 4-8 and 8-12 h after drug administration, the volume was measured, and a 5 ml aliquot was stored at -70°C until analysis. The percentage of drug excreted in the dosing interval was calculated by dividing the total amount excreted by the dose given.
Sample analysis
Drug concentrations in serum, sputum and urine were measured with an agar cup assay (Lautrop et al., 1979) with Escherichia coli V63 (State Serum institute, Denmark) as the test strain. Reference standards for serum and sputum levels were made in pooled human serum and standards for urine in phosphate buffered saline (pH 7-2). All samples were tested in duplicate. The lower detection limit of the assay was 013 mg/1.
Pharmacokinetic analysis
The area under the serum concentration-time curve from 0 to 12 h (AUCo_ 12 ) was calculated by the trapezoidal rule. The absorption fraction of the drugs in CF patients is unknown and the apparent serum clearance of each drug was calculated from the equation: C/, pp = dose/AUC 0 _ 12 (at steady state). Renal clearance was calculated as C/ ren = AJAUC, where A. is the total amount of drug excreted in the urine during the dosing interval. Non-renal clearance Cl^n^ was equal to Cl^,-Cl m . All clearances were corrected for body weight. Mean serum concentration (C",) was calculated as AUC/12 h. The elimination rate constant (k cl ) was calculated by the equation k t , = 2-303 x slope of the logarithmic plot of the serum-concentration-time curve for each patient and the slope was obtained by linear regression analysis of the elimination phase. The terminal half-life, T l/2/ = 0-693/fc e) . All data were expressed as arithmetric means ± 1 standard deviation.
Dose-response
To determine whether any pharmacokinetic variables would correlate with clinical efficacy, the change in pulmonary function tests (i.e. forced vital capacity and forced expiratory volume in the first second seen during treatment) was used as an index of clinical response. The following pharmacokinetic parameters were tested: maximum serum concentration, AUC, mean serum concentration, time serum level > MIC, C/ ipp , sputum concentration and AUC > MIC ('effective AUC).
Sensitivity of P. aeruginosa
The MICs of ciprofloxacin and ofloxacin for all strains of P. aeruginosa isolated from the patients during treatment were determined by an agar dilution method with an inoculum of 10 3 -10 4 cfu (Lautrop et al., 1979) . In comparison of serum concentrations of the drugs with the susceptibility of P. aeruginosa the MIC of the most resistant strain isolated during treatment was used.
Statistical analysis
The statistical difference of pharmacokinetic data between ciprofloxacin and ofloxacin was determined by the paired t-test. The level of significance was 005 (two-tailed). Table I show the mean serum concentrations of ciprofloxacin and ofloxacin. Pharmacokinetic data are summarized in Table II . Serum concentrations of ofloxacin were higher than those of ciprofloxacin (C mMl : 5-9 vs. 40 mg/1; C t ; 3-2 vs. 1-6 mg/1). Likewise the AUC was twice as big (38-5 vs. 19-3 mg/h/1) although the dose of ofloxacin per kg body weight was lower. The time to reach maximal serum concentration did not differ indicating that both drugs were readily absorbed. The apparent total body clearance of ciprofloxacin was significantly greater than that of ofloxacin, whereas renal clearance was identical. The half-life of ciprofloxacin was Table I significantly (P < 001, t = 4-10) shorter than that of ofloxacin {T int = 3-4 h versus 6-4 h).
Results
Figure 1 and
The ciprofloxacin concentration in serum exceeded the MIC of the least sensitive strain of P. aeruginosa for more than 3/4 of the dosing interval whereas the concentration of ofloxacin exceeded its MIC for more than half the dosing interval. The difference was not statistically significant. The mean concentration of ofloxacin in sputum was more than five-fold higher than that of ciprofloxacin (2-8 vs. 0-5 mg/1; Table III , P < 001, / = 7-57) (Table III) . Ofloxacin penetrated significantly better into sputum than did ciprofloxacin as the ratios of sputum level to serum level at 2 h were 79% and 18% respectively (t = 507, P < 001). For each drug the number of patients in whom the sputum concentration exceeded the MIC was calculated. Sputum Table III concentrations of ciprofloxacin at 2 h exceeded the MIC of P. aeruginosa, in five of 18 patients vs. 10 of 18 patients who received ofloxacin. The observed difference was not statistically significant. Seventy-one per cent of the administered dose of ofloxacin was recovered from urine within 12 h, whereas only 21% of the ciprofloxacin dose could be recovered as biologically active substance by the microbiological assay (Table FV, 
f = 6-90, P<00\).
No correlation could be demonstrated between any of the obtained pharmacokinetic variables and the change in pulmonary function.
Discussion
In the clinical part of this comparative study ciprofloxacin and ofloxacin were found equally effective-in the administered doses-in improving the clinical conditions of the patients. Furthermore, the tolerability of the two drugs and the development of resistance were comparable (Jensen et al., 1987) .
The pharmacokinetic results of oral ciprofloxacin in CF-patients from the present study and four other studies (Bender et al., 1986; Goldfarb et al., 1986; LeBel et al., 1986; Smith et al., 1986b) are summarized in Table V . The majority of previous studies were of a single dose and none incorporated a dose of 750 mg ciprofloxacin bid. If corrected for different dosages, C mMX and AUC of our study are in the range of the results of the other groups. However, Bender et al. (1986) found a considerably longer terminal half-life of ciprofloxacin. In the study of LeBel et al. (1986) the half-life of ciprofloxacin in CF was significantly shorter than in healthy volunteers. Whereas we found the apparent total body clearance in the same range as observed by LeBel et al. (1986) the renal clearance found by us is considerably lower than reported by LeBel et al. (1986) and Bender et al. (1986) . Our data seem to be more at variance when comparing sputum levels of ciprofloxacin. Goldfarb et al. (1986) reported that ciprofloxacin sputum concentrations were still increasing four hours after a dose, whereas Smith et al. (1986b) recorded peak sputum concentrations at 20±10h. However, both authors considered the concentration obtained to be satisfactorily above the MIC 90 of P. aeruginosa. This is in contrast to our observation that sputum concentrations only exceeded the MIC of P. aeruginosa isolated from the patients in five of 18 patients. An increase in MIC was seen in P. aeruginosa isolated from our patients during treatment (Jensen et al., 1987) and this may in part explain this observation. 
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Few studies have been published on the pharmacokinetics of ofloxacin (Lockley, Wise & Dent, 1984; Kalager et aL, 1986; Leroy et aL, 1987) and none in patients with cystic fibrosis. Our data on ofloxacin are, despite different dosages, in good agreement with these studies, showing rapid absorption, high C,^, an elimination half-life in serum between 6 and 7 h and high urinary recovery. Ofloxacin showed significantly higher serum concentrations, higher penetration into sputum and higher urinary recovery of biologically active metabolites than did ciprofloxacin. However, there were no difference between the two drugs when duration in which serum concentrations exceeded the MIC of P. aeruginosa, or the number of patients in whom effective sputum levels were obtained, were compared.
Malabsorption, due to pancreatic insufficiency, is a major feature of CF. This may also affect the absorption of antibiotics, but no data are available on the bioavailability of the two quinolones in CF-patients. In volunteers the bioavailability of ciprofloxacin has been found to be approximately 70% (Hoffken et aL, 1985; Drusano et aL, 1986) . If the apparent body clearance of the present study is corrected by this figure the total body clearance will be in the range of 9 ml/min/kg. However, renal clearance has been found to account for more than 60% of the total clearance of ciprofloxacin (Hoffken et al., 1985) , and according to the above calculation C/ ren would be only about 30%. It seems reasonable, therefore, to assume a lower bioavailability of ciprofloxacin in CF, which would also explain the low urinary recovery. No data on bioavailability or total body clearance, other than the apparent clearance, of ofloxacin have been published. However, the problem of bioavailability of ofloxacin may be of less significance as the urinary excretion is much higher.
Pharmacokinetic data would prove clinically useful if they predicted clinical response. In a neutropenic mouse model a highly significant correlation between logi 0 AUC and efficacy of ciprofloxacin could be demonstrated (Vogelman et aL, 1986) . In our experience, pulmonary function tests are the most suitable way of grading clinical efficacy of antimicrobial treatment in CF-patients. However, no variation in any of the individual pharmacokinetic data obtained correlated with the degree of response.
In conclusion, it seems that despite the differences demonstrated in this study between the pharmacokinetics of ciprofloxacin and ofloxacin in CF-patients no preference can be advanced with respect to clinical performance for these two quinolones. CF patients with chronic P. aeruginosa infection require repeated courses of antipscudomonal chemotherapy, commonly for many years. If, however, the quinolones are to be used extensively in the future, the cost of the treatment may become a decisive factor in the choice of preparation.
